Thrombophilia and risk of venous thrombosis in patients with cancer (Q37006639)

17 August 2017

1 reference

title

Thrombophilia and risk of venous thrombosis in patients with cancer (English)

1 reference

17 August 2017

0 references

1 reference

Hervé Decousus

1

1 reference

17 August 2017

Nathalie Moulin

2

1 reference

17 August 2017

Sara Quenet

3

1 reference

17 August 2017

Vincent Bost

4

1 reference

17 August 2017

Karine Rivron-Guillot

5

1 reference

17 August 2017

Silvy Laporte

6

1 reference

17 August 2017

Patrick Mismetti

7

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

120 Suppl 2

1 reference

17 August 2017

page(s)

S51-61

1 reference

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Cancer and venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Chronic venous disease, inflammation, and Daflon 500 mg.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Mutation in blood coagulation factor V associated with resistance to activated protein C.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

1 reference

7 January 2021

Clinical significance of the FV:Q506 mutation in unselected oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

The factor V Leiden mutation in children with cancer and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Preventing complications of central venous catheterization

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Factor V Leiden mutation does not account for central venous catheter-related thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Factor V Leiden in central venous catheter-associated thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Risk factors for catheter-related thrombosis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Venous thromboembolism: disease burden, outcomes and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Acquired resistance to activated protein C in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Acquired activated protein C resistance and thrombosis in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Hypercoagulable states in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Genetic and plasma markers of venous thromboembolism in patients with high grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Potential risk of a common hereditary thrombophilia and adjuvant chemotherapy for low-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Chemotherapy for breast cancer decreases plasma protein C and protein S.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Venous thromboembolism and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

The etiologic distribution of thrombophilic factors in chronic portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Epidemiology of thrombosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Incidence of venous thromboembolism and the impact on survival in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2807%2970130-5

7 January 2021

10.1016/S0049-3848(07)70130-5

Identifiers

DOI

1 reference

17 August 2017

1 reference